India, Feb. 10 -- Sanofi Healthcare India has announced receipt of marketing authorisation for Rezurock(Belumosudil Tablets) in India. Rezurockrepresents a new, best-in-class treatment paradigm for thousands of cGVHD patients globally (12 years and above), after failure of two previous lines of treatment, including those with difficult-to-treat manifestations like fibrosis.

Rezurockwas approved by the US FDA(in 2021) and by the CDSCOin India (in 2024) based on safety and efficacy results from ROCKstar - a randomised, open-label, multicenter pivotal trial of Rezurockin patients with cGVHD who had received two to five prior lines of systemic therapy.

Administered once daily (orally), Rezurock200 mg achieved an Overall Response Rate (ORR)o...